Sartorius Stedim Biotech Past Earnings Performance
Past criteria checks 4/6
Sartorius Stedim Biotech's earnings have been declining at an average annual rate of -14%, while the Life Sciences industry saw earnings growing at 6.7% annually. Revenues have been growing at an average rate of 4.6% per year. Sartorius Stedim Biotech's return on equity is 6.5%, and it has net margins of 9%.
Key information
-13.95%
Earnings growth rate
-14.61%
EPS growth rate
| Life Sciences Industry Growth | 26.83% |
| Revenue growth rate | 4.64% |
| Return on equity | 6.51% |
| Net Margin | 8.96% |
| Last Earnings Update | 30 Sep 2025 |
Recent past performance updates
Recent updates
Is Sartorius Stedim Biotech S.A. (EPA:DIM) Potentially Undervalued?
Oct 17
Is There An Opportunity With Sartorius Stedim Biotech S.A.'s (EPA:DIM) 21% Undervaluation?
Aug 29Is There Now An Opportunity In Sartorius Stedim Biotech S.A. (EPA:DIM)?
Jul 17Is Sartorius Stedim Biotech (EPA:DIM) A Risky Investment?
Jul 01What Sartorius Stedim Biotech S.A.'s (EPA:DIM) 30% Share Price Gain Is Not Telling You
May 10Results: Sartorius Stedim Biotech S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 19Is Now The Time To Look At Buying Sartorius Stedim Biotech S.A. (EPA:DIM)?
Apr 10Sartorius Stedim Biotech S.A. (EPA:DIM) Shares Could Be 25% Above Their Intrinsic Value Estimate
Mar 26Sartorius Stedim Biotech S.A.'s (EPA:DIM) Shareholders Might Be Looking For Exit
Feb 07Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?
Dec 27
Increased Order Intake And Efficiency Drive Future Growth Amidst Global Challenges
Increased order intake for consumables indicates future recurring revenue stability as customer destocking improves, highlighting positive growth trends.Sartorius Stedim Biotech's (EPA:DIM) Weak Earnings May Only Reveal A Part Of The Whole Picture
Oct 25Revenue & Expenses Breakdown
How Sartorius Stedim Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 25 | 2,947 | 264 | 667 | 139 |
| 30 Jun 25 | 2,896 | 225 | 665 | 146 |
| 31 Mar 25 | 2,858 | 204 | 656 | 149 |
| 31 Dec 24 | 2,780 | 175 | 650 | 144 |
| 30 Sep 24 | 2,736 | 161 | 641 | 143 |
| 30 Jun 24 | 2,747 | 170 | 636 | 134 |
| 31 Mar 24 | 2,716 | 255 | 625 | 129 |
| 31 Dec 23 | 2,776 | 310 | 618 | 130 |
| 30 Sep 23 | 2,959 | 460 | 598 | 131 |
| 30 Jun 23 | 3,170 | 635 | 619 | 132 |
| 31 Mar 23 | 3,356 | 717 | 604 | 135 |
| 31 Dec 22 | 3,493 | 876 | 612 | 132 |
| 30 Sep 22 | 3,381 | 681 | 605 | 125 |
| 30 Jun 22 | 3,259 | 625 | 577 | 123 |
| 31 Mar 22 | 3,094 | 559 | 564 | 119 |
| 31 Dec 21 | 2,887 | 414 | 532 | 111 |
| 30 Sep 21 | 2,639 | 523 | 479 | 103 |
| 30 Jun 21 | 2,393 | 469 | 450 | 98 |
| 31 Mar 21 | 2,143 | 398 | 417 | 89 |
| 31 Dec 20 | 1,910 | 336 | 392 | 84 |
| 30 Sep 20 | 1,743 | 299 | 373 | 84 |
| 30 Jun 20 | 1,600 | 255 | 353 | 81 |
| 31 Mar 20 | 1,520 | 254 | 334 | 81 |
| 31 Dec 19 | 1,441 | 235 | 318 | 79 |
| 30 Sep 19 | 1,393 | 247 | 308 | 68 |
| 30 Jun 19 | 1,336 | 238 | 301 | 65 |
| 31 Mar 19 | 1,274 | 223 | 293 | 61 |
| 31 Dec 18 | 1,212 | 208 | 283 | 61 |
| 30 Sep 18 | 1,172 | 185 | 277 | 60 |
| 30 Jun 18 | 1,121 | 173 | 264 | 59 |
| 31 Mar 18 | 1,093 | 162 | 259 | 57 |
| 31 Dec 17 | 1,081 | 161 | 258 | 53 |
| 30 Sep 17 | 1,073 | 151 | 252 | 53 |
| 30 Jun 17 | 1,089 | 157 | 255 | 50 |
| 31 Mar 17 | 1,075 | 157 | 250 | 49 |
| 31 Dec 16 | 1,052 | 154 | 244 | 48 |
| 30 Sep 16 | 1,009 | 145 | 242 | 47 |
| 30 Jun 16 | 971 | 142 | 234 | 46 |
| 31 Mar 16 | 926 | 136 | 226 | 43 |
| 31 Dec 15 | 884 | 118 | 217 | 42 |
| 30 Sep 15 | 850 | 111 | 207 | 43 |
| 30 Jun 15 | 781 | 89 | 197 | 35 |
| 31 Mar 15 | 734 | 76 | 189 | 39 |
| 31 Dec 14 | 684 | 72 | 184 | 34 |
Quality Earnings: DIM has high quality earnings.
Growing Profit Margin: DIM's current net profit margins (9%) are higher than last year (5.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DIM's earnings have declined by 14% per year over the past 5 years.
Accelerating Growth: DIM's earnings growth over the past year (64.3%) exceeds its 5-year average (-14% per year).
Earnings vs Industry: DIM earnings growth over the past year (64.3%) exceeded the Life Sciences industry 18.2%.
Return on Equity
High ROE: DIM's Return on Equity (6.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/24 00:15 |
| End of Day Share Price | 2025/10/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sartorius Stedim Biotech S.A. is covered by 33 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |
| Julien Dormois | BNP Paribas Exane |